0OO9 Stock Chart & Stats
€44.35
€0.63(1.43%)
At close: 4:00 PM EDT
€44.35
€0.63(1.43%)
Day’s Range― - ―
52-Week Range€35.13 - €52.82
Previous CloseN/A
Volume1.23K
Average Volume (3M)252.50K
Market Cap
€23.62B
Enterprise Value€33.35B
Total Cash (Recent Filing)€1.28B
Total Debt (Recent Filing)€11.42B
Price to Earnings (P/E)15.4
Beta1.02
Next Earnings
Nov 04, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.75
Shares Outstanding563,237,300
10 Day Avg. Volume199,385
30 Day Avg. Volume252,500
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.30Price Target Upside24.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)3.67
Revenue Forecast (FY)€23.76B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryThe return to positive net profitability, supported by solid operating and EBITDA margins, indicates that the business has rebuilt earnings power after the 2023 loss. If maintained across Helios, Kabi and FMC-related operations, this recovery can support reinvestment and strengthen financial resilience over the next several quarters.
Meaningful DeleveragingThe substantial reduction in debt relative to equity lowers financial risk and gives Fresenius greater flexibility to fund operations, invest in its healthcare businesses, or withstand pressure in reimbursement and utilization. A stronger balance sheet also makes the earnings recovery more durable than one dependent on higher leverage.
Biosimilar Platform ExpansionThe mAbxience-Sandoz agreement expands Fresenius’s exposure to biosimilars by combining development and manufacturing capabilities with global commercialization reach. Although financial terms are undisclosed and the product remains a candidate, the arrangement could broaden Kabi-related growth opportunities and patient access over time.
Bears Say
Weakening Cash ConversionPositive cash flow is being generated, but the decline in free cash flow and conversion at roughly half of net income reduce confidence that accounting earnings are translating consistently into distributable cash. Persistent working-capital or capital-spending demands could constrain debt reduction, investment, and shareholder returns.
Uneven Revenue TrajectoryCurrent revenue momentum benefits from recovery versus the weak 2023 base, yet the sharp prior decline shows that Fresenius has not established a consistently smooth growth path. Uneven top-line performance can make capacity planning and margin improvement harder and leaves results more dependent on recovery execution.
Returns Remain Below Prior PeaksThe rebound in returns is encouraging, but ROE remains below the earlier 2021 level and the recovery has not restored prior profitability highs. This suggests asset efficiency or operating performance is not yet fully normalized, which may limit the pace at which Fresenius compounds earnings from its healthcare platform.
Fresenius SE & Co. KGaA News
0OO9 FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest share price was €35.13 and its highest was €52.82 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Fresenius SE & Co. KGaA’s market cap is €23.62B.
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Nov 04, 2026 which is in 22 days.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Fresenius SE & Co. KGaA released its earnings results on Aug 04, 2026. The company reported €0.83 earnings per share for the quarter, missing the consensus estimate of €0.889 by -€0.059.
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA does not currently pay dividends.
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is 0.77.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Fresenius SE & Co. KGaA reported an EPS of €0.83 in its last earnings report, missing expectations of €0.889. Following the earnings report the stock price went down -0.692%.
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in GB:0OO9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co. KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€55.30 (24.69% Upside)
€55.30 (24.69% Upside)
Insider Transactions
Bought Shares
Worth €297.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.71%
12-Months-Change
Fundamentals
Return on Equity
7.89%
Trailing 12-Months
Asset Growth
1.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
0OO9 Stock 12 Month Forecast
Average Price Target
€55.30
▲(24.69% Upside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius Medical Care AG & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―








